Posted by Michael Wonder on 27 Jan 2019

Tanvex submits new drug submission for TX01 to Health Canada

Tanvex BioPharma
Back on November 2018, the US FDA accepted Tanvex BioPharma’s biologics license application for TX-01 (filgrastim), a proposed biosimilar to the reference product Neupogen (filgrastim) which is indicated for chemotherapy induced neutropenia. 

Today, Tanvex BioPharma is proud to also announce its new drug submission to the Health Canada for filgrastim.

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Canada , Biosimilar , Dossier